Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
33
SKYE Quote, Financials, Valuation and Earnings
Last price:
$1.10
Seasonality move
:
-20.14%
Day range:
$0.87 - $1.07
52-week range:
$0.68 - $5.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
476.49x
P/B ratio:
0.99x
Volume:
1M
Avg. volume:
466.1K
1-year change:
-65.99%
Market cap:
$32.4M
Revenue:
--
EPS (TTM):
-$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
-- | -$0.31 | -- | -25.79% | $8.25 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
FGEN
FibroGen, Inc.
|
$1.7M | -$4.17 | -46.75% | -5.74% | $43.00 |
|
MYO
Myomo, Inc.
|
$10.4M | -$0.09 | -13.8% | -1168.66% | $5.00 |
|
TBPH
Theravance Biopharma, Inc.
|
$43M | -$0.05 | 129.3% | -80.69% | $26.71 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.90 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
$1.01 | $8.25 | $32.4M | -- | $0.00 | 0% | 476.49x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
FGEN
FibroGen, Inc.
|
$9.02 | $43.00 | $36.5M | 0.23x | $0.00 | 0% | 30.72x |
|
MYO
Myomo, Inc.
|
$1.02 | $5.00 | $39.2M | -- | $0.00 | 0% | 1.00x |
|
TBPH
Theravance Biopharma, Inc.
|
$18.30 | $26.71 | $927.3M | 32.53x | $0.00 | 0% | 11.48x |
|
VKTX
Viking Therapeutics, Inc.
|
$32.30 | $93.39 | $3.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
0.97% | 6.143 | 0.26% | 4.22x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
FGEN
FibroGen, Inc.
|
524.43% | 0.950 | 25.04% | 3.28x |
|
MYO
Myomo, Inc.
|
45.68% | -2.417 | 35.87% | 1.94x |
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.446 | 6.03% | 9.30x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 0.864 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SKYE
Skye Bioscience, Inc.
|
-$178.9K | -$13.3M | -91.01% | -91.57% | -- | -$13.4M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
FGEN
FibroGen, Inc.
|
$942K | -$5.4M | -- | -- | -499.07% | -$1.9M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Skye Bioscience, Inc. vs. Competitors
-
Which has Higher Returns SKYE or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -12425.36%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About SKYE or CATX?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 716.83%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Skye Bioscience, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is SKYE or CATX More Risky?
Skye Bioscience, Inc. has a beta of 2.680, which suggesting that the stock is 168.024% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock SKYE or CATX?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or CATX?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Skye Bioscience, Inc.'s net income of -$12.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns SKYE or FGEN?
FibroGen, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -1221.75%. Skye Bioscience, Inc.'s return on equity of -91.57% beat FibroGen, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M FGENFibroGen, Inc.87.55% $36.71 $38.5M -
What do Analysts Say About SKYE or FGEN?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 716.83%. On the other hand FibroGen, Inc. has an analysts' consensus of $43.00 which suggests that it could grow by 376.72%. Given that Skye Bioscience, Inc. has higher upside potential than FibroGen, Inc., analysts believe Skye Bioscience, Inc. is more attractive than FibroGen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 FGENFibroGen, Inc.0 1 0 -
Is SKYE or FGEN More Risky?
Skye Bioscience, Inc. has a beta of 2.680, which suggesting that the stock is 168.024% more volatile than S&P 500. In comparison FibroGen, Inc. has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.267%.
-
Which is a Better Dividend Stock SKYE or FGEN?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. FibroGen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or FGEN?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than FibroGen, Inc. quarterly revenues of $1.1M. Skye Bioscience, Inc.'s net income of -$12.8M is higher than FibroGen, Inc.'s net income of -$13.1M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while FibroGen, Inc.'s PE ratio is 0.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 30.72x for FibroGen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M FGENFibroGen, Inc.30.72x 0.23x $1.1M -$13.1M
-
Which has Higher Returns SKYE or MYO?
Myomo, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of -36.3%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About SKYE or MYO?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 716.83%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Skye Bioscience, Inc. has higher upside potential than Myomo, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Myomo, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 MYOMyomo, Inc.4 0 0 -
Is SKYE or MYO More Risky?
Skye Bioscience, Inc. has a beta of 2.680, which suggesting that the stock is 168.024% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.
-
Which is a Better Dividend Stock SKYE or MYO?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or MYO?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Skye Bioscience, Inc.'s net income of -$12.8M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M MYOMyomo, Inc.1.00x -- $10.1M -$3.7M
-
Which has Higher Returns SKYE or TBPH?
Theravance Biopharma, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of 18.08%. Skye Bioscience, Inc.'s return on equity of -91.57% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M -
What do Analysts Say About SKYE or TBPH?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 716.83%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 45.98%. Given that Skye Bioscience, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 TBPHTheravance Biopharma, Inc.5 2 0 -
Is SKYE or TBPH More Risky?
Skye Bioscience, Inc. has a beta of 2.680, which suggesting that the stock is 168.024% more volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.139, suggesting its less volatile than the S&P 500 by 86.12%.
-
Which is a Better Dividend Stock SKYE or TBPH?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or TBPH?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. Skye Bioscience, Inc.'s net income of -$12.8M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 32.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus 11.48x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M TBPHTheravance Biopharma, Inc.11.48x 32.53x $20M $3.6M
-
Which has Higher Returns SKYE or VKTX?
Viking Therapeutics, Inc. has a net margin of -- compared to Skye Bioscience, Inc.'s net margin of --. Skye Bioscience, Inc.'s return on equity of -91.57% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital SKYESkye Bioscience, Inc.-- -$0.32 $33.2M VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About SKYE or VKTX?
Skye Bioscience, Inc. has a consensus price target of $8.25, signalling upside risk potential of 716.83%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 189.13%. Given that Skye Bioscience, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Viking Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SKYESkye Bioscience, Inc.4 2 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is SKYE or VKTX More Risky?
Skye Bioscience, Inc. has a beta of 2.680, which suggesting that the stock is 168.024% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.988%.
-
Which is a Better Dividend Stock SKYE or VKTX?
Skye Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SKYE or VKTX?
Skye Bioscience, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Skye Bioscience, Inc.'s net income of -$12.8M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Skye Bioscience, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience, Inc. is 476.49x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
